XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
Organization and Nature of Business (Details) - USD ($)
 3 Months Ended
Sep. 09, 2021
Nov. 01, 2019
Sep. 30, 2022
Cash upon completion of Phase I Clinical Trials   $ 1,500,000  
Cash upon completion of Phase II Clinical Trials   2,500,000  
Cash upon completion of Phase III Clinical Trials   $ 5,000,000  
TheraCour Pharma Inc      
Percentage of net sales allocated for royalty payments   15.00% 15.00%
Series A Convertible Preferred Stock | TheraCour Pharma Inc      
Percentage of net sales allocated for royalty payments 15.00%    
Cash upon completion of Phase I Clinical Trials $ 2,000,000    
Cash upon completion of Phase II Clinical Trials 2,500,000    
Cash upon completion of Phase III Clinical Trials $ 5,000,000    
Number of shares issuable upon execution of agreement 100,000    
Threshold period for issuance of shares upon execution of agreement 30 days    
Issuance of shares upon the approval 50,000    
Initiation of Phase I Clinical Trials Values $ 1,500,000    
Number of Shares upon initiation of Phase III Clinical Trials 100,000    
Number of Shares upon Completion of Phase III Clinical Trials 500,000    
Series A Preferred stock      
Issuance of shares   75,000